Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 9/20 | 1.00 |
| ▸ | ABCC8 | Q09428 | 9/20 | 1.00 |
| ▸ | KCNJ11 | Q14654 | 9/20 | 1.00 |
| ▸ | KCNJ8 | Q15842 | 9/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 9/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 9/20 | 0.56 |
| ▸ | PDK3 | Q15120 | 9/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 9/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7832380 | 0.81 | ABCC9 (0.67) | ABCC9ABCC8KCNJ11KCNJ8PDK1 | |
| SCHEMBL5111868 | 0.78 | MAOA (0.81) | ABCC9ABCC8KCNJ11KCNJ8MAOA | |
| SCHEMBL7833541 | 0.78 | LCK (0.68) | ABCC9ABCC8KCNJ11KCNJ8PDK1 | |
| SCHEMBL5766745 | 0.78 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8PDK1 | |
| SCHEMBL5116247 | 0.75 | ABCC9 (0.60) | ABCC9ABCC8KCNJ11KCNJ8PDK2 | |
| SCHEMBL6339286 | 0.75 | ABCC9 (0.60) | ABCC9ABCC8KCNJ11KCNJ8PDK2 | |
| SCHEMBL7829732 | 0.73 | ABCC9 (0.58) | ABCC9ABCC8KCNJ11KCNJ8PDK1 | |
| SCHEMBL6416133 | 0.73 | ABCC9 (0.57) | ABCC9ABCC8KCNJ11KCNJ8PDK2 | |
| SCHEMBL5110259 | 0.73 | ABCC9 (0.57) | ABCC9ABCC8KCNJ11KCNJ8PDK2 | |
| SCHEMBL5767979 | 0.73 | ABCC9 (0.57) | ABCC9ABCC8KCNJ11KCNJ8PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | disclosed |
| US-20050209233-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-09-22 | — | — | US | disclosed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209233-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | NPY5R, NPY1R, NPY2R | ABCC9 3402/4885ABCC8 3798/4885KCNJ11 3207/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | ABCC9 4182/4885ABCC8 4453/4885KCNJ11 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.